In The News

13 April 2022

Getting through the Corona pandemic with AKS-452 vaccines

7 April 2022

COVID-19 vaccine: Akston Biosciences doses first volunteers in Phase II/III trial

18 March 2022

Will the Second Wave of COVID-19 Vaccines Have the Improved Properties Needed to End the Pandemic?

17 March 2022

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

17 March 2022

Stelis Licenses Akston’s AKS-452 Thermostable Protein Subunit COVID Vax

17 March 2022

2nd Generation COVID-19 Vaccine Available in 130+ Countries

8 February 2022

Easier-To-Produce Room Temperature Covid Shot Shows Promise In Early Clinical Trials

6 January 2022

Akston Biosciences seeks USD 10m–25m raise, plans for further COVID-19 vaccine booster trials

2 December 2021

What will tomorrow’s Covid-19 vaccines be like?

11 November 2021

‘Looking forward to second-gen vaccines,’ says WHO chief: From nasal sprays to multivariant jabs, vaccines in development spur hope of ending the pandemic